About the
NeLM
|
Help & Support
|
Site Feedback
|
Update Newsletter Subscription
Homepage
Login
|
Register
Search the NeLM
Medicines A-Z
Find key information about medicines by name (prototype)
Browse by Categories:
BNF Category
|
Medical Specialty
|
National Health Service
|
Medicines Information
Browse by NeLM area:
Evidence
|
Other Library Updates
|
News
|
Health In Focus
|
Medicines A-Z
|
Communities
|
Useful Links
|
Formularies
BNF Category
1: Gastro-intestinal system
2: Cardiovascular system
3: Respiratory system
4: Central nervous system
5: Infections
6: Endocrine system
7: Obstetrics, gynaecology, and urinary-tract disorders
8: Malignant disease and immunosuppression
9: Nutrition and blood
10: Musculoskeletal and joint diseases
11: Eye
12: Ear, nose, and oropharynx
13: Skin
14: Immunological products and vaccines
15: Anaesthesia
Appendix 7
Appendix 8 Wound management products and elasticated garments
Non-BNF miscellaneous
Emergency treatment of poisoning
10.1 Drugs used in rheumatic diseases and gout
10.2 Drugs used in neuromuscular disorders
10.3 Drugs for the relief of soft-tissue inflammation and topical pain relief
1377 library items
in 10: Musculoskeletal and joint diseases
Filter results by:
Date Published
2012 (68)
2011 (244)
2010 (234)
2009 (216)
2008 (181)
More
NeLM
Area
News
Other Library Updates
Health In Focus
Evidence
Medicines A-Z
Communities
Formularies
Results filtered by:
Category
10: Musculoskeletal and joint diseases (
remove
)
Sort by:
Least recent publication date
Most recent publication date
Title alphabetical A-Z
Title alphabetical Z-A
Source alphabetical A-Z
Source alphabetical Z-A
Display summary:
No
Yes
Results 1 - 10 of 1377
Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next
1.
SMC accepts collagenase (Xiapex®) for restricted use in the treatment of Dupuytren’s contracture
Source:
Scottish Medicines Consortium (SMC)
,
Date published:
15/05/2012
Category:
10.3.1 Enzymes
|
Drug reviews
|
Rheumatology
|
Scottish Medicines Consortium
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link to drug advice
2.
Cohort study: Incidence of hospitalised bacterial infection associated with juvenile idiopathic arthritis and its treatment
Source:
Arthritis and Rheumatism
,
Date published:
14/05/2012
Category:
10.1.3 Drugs that suppress the rheumatic disease process
|
Adverse Drug Reactions
|
Bacterial
|
Rheumatology
NeLM
Area:
News
Abstract
3.
Horizon scanning: FDA advisory panel recommends approval of tofacitinib for adult patients with moderately to severely active rheumatoid arthritis
Source:
PharmaLive
,
Date published:
10/05/2012
Category:
10.1.3 Drugs that suppress the rheumatic disease process
|
Food &Drug Administration (FDA)
|
Horizon scanning
|
Rheumatoid Arthritis
NeLM
Area:
News
Link
4.
NHS Evidence’expert commentary: Acute and subacute neck pain
Source:
NHS Evidence
,
Date published:
10/05/2012
Category:
4.7.1 Non-opioid analgesics and compound analgesic preparations
|
10.1.1 Non-steroidal anti-inflammatory drugs
|
Rheumatology
NeLM
Area:
News
Link to registration page for Eyes on Evidence
Link to back copies of Eyes on Evidence
5.
FDA advisory panel rejects approval of rilonacept (Arcalyst®) injection for prevention of gout flares in patients initiating uric acid-lowering therapy
Source:
BioSpace
,
Date published:
10/05/2012
Category:
10.1.4 Gout and cytotoxic-induced hyperuricaemia
|
Food &Drug Administration (FDA)
|
Gout
|
New drugs
NeLM
Area:
News
Link
6.
Horizon scanning: Study suggests subcutaneous formulation of tocilizumab is of comparable efficacy to IV formulation
Source:
BioSpace
,
Date published:
04/05/2012
Category:
10.1.3 Drugs that suppress the rheumatic disease process
|
Drug Administration
|
Rheumatoid Arthritis
NeLM
Area:
News
Link
7.
Improvement of the drug allergy alert for nonprescription NSAIDs
Source:
Drug Information Journal
,
Date published:
02/05/2012
Category:
10.1.1 Non-steroidal anti-inflammatory drugs
|
Adverse Drug Reactions
|
OTC medicines
|
Patient
NeLM
Area:
Evidence
>
Medicines Management
>
References
Abstract link
8.
AWMSG issues Final Appraisal Recommendation on use of adalimumab (Humira®) for active polyarticular juvenile idiopathic arthritis
Source:
All Wales Medicines Strategy Group (AWMSG)
,
Date published:
01/05/2012
Category:
10.1.3 Drugs that suppress the rheumatic disease process
|
All Wales Medicines Strategy Group (AWMSG)
|
Paediatrics
|
Rheumatoid Arthritis
NeLM
Area:
Evidence
>
Drug Specific Reviews
Link
9.
Final draft NICE guidance does not support the use of belimumab for treating SLE
Source:
NICE
,
Date published:
27/04/2012
Category:
10.1.3 Drugs that suppress the rheumatic disease process
|
National Institute of Clinical Excellence (NICE)
|
Systemic Lupus Erythematosus
NeLM
Area:
News
Final draft guidance (FAD)
Press release
Previous NeLM report on SMC guidance
10.
Should rheumatology patients on immunosuppressive medications be advised against getting tattoos?
Source:
Irish Medical Journal
,
Date published:
27/04/2012
Category:
10.1.3 Drugs that suppress the rheumatic disease process
NeLM
Area:
Evidence
>
Medicines Management
>
References
Full text link
Results 1 - 10 of 1377
Result page:
Previous
|
1
2
3
4
5
6
7
8
9
10
11
|
Next